Many corporate-backed funds remain enthusiastic venture investors, but some might be hitting the brakes.
Evaluate Vantage's coverage of the virtual AACR 2021 congress.
A radionuclide deal between Lantheus and Noria mirrors that done by Novartis and Sofie, among others.
The company might finally become an oncology player.
Boehringer says its inhaled antibody could reach the patients IV antibodies cannot, but will be “very happy” if it isn’t needed.
Since 2010 14% of US accelerated approvals have been granted to Merck & Co’s Keytruda.